Novavax CEO To Jim Cramer: 'We Are In For An Exciting Year'

Novavax, Inc. NVAX CEO Stanley Erck was a guest on Jim Cramer's "Mad Money" segment on Tuesday.

Novavax is a clinical stage-vaccine company that targets known and newly emerging diseases. Its stock has lost around 20 percent since the start of 2016 more than 50 percent since peaking at $15.01 last summer.

Speaking to Cramer, Novavax's CEO Stanley Erck defended his company after capping off a "terrific year" in 2015.

"We started the year initiating five clinical trials, and we unblended the trials and all the data were great," Erck said. "We are in for an exciting year."

Erck further explained that the company vaccinated 11,850 patients last month and will focus on compiling the data in the third quarter, The Street reported. Accordingly, the company is on a "predictable path" and shouldn't experience any surprises.

Finally, Cramer argued that once the negative sentiment in the market passes, companies that are doing well, like Novavax, will see its sentiment improve.